A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. AbCellera Biologics Inc’s current trading price is -0.58% away from its 52-week high, while its distance from the 52-week low is 127.71%. The stock’s price range for this time frame has been between $1.89 and $4.33. The trading volume of the company’s shares in the Healthcare reached around 3.8 million for the day, which was evidently lower than the average daily volume of 5.47 million over the last three months.
AbCellera Biologics Inc (ABCL) currently has a stock price of $4.3. The stock saw a sharp increase in the last trading session, hitting a high of $17.0 after opening at $4.37. The lowest recorded price for the day was $5.0 before it closed at $4.01.
AbCellera Biologics Inc’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $4.33 on 07/14/25, and the lowest price during that time was $1.89, recorded on 04/07/25.
How Financial Performance Impacts Market Capitalization
AbCellera Biologics Inc (ABCL) has experienced a quarterly rise of 107.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.28B and boasts a workforce of 596 employees.
Decoding Analysts’ Ratings for AbCellera Biologics Inc
As of right now, 6 analysts are rating AbCellera Biologics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.64, with a change in price of +0.94. Similarly, AbCellera Biologics Inc recorded 5,013,217 in trading volume during the last 100 days, posting a change of +27.41%.
How ABCL’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
ABCL Stock Stochastic Average
AbCellera Biologics Inc’s raw stochastic average for the past 50 days is currently at 98.78%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 97.89%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 89.42% and 90.18%, respectively.
ABCL Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Year to date metric has recorded a gain of 53.75%.However, over the last six months, we can see a weaker performance of 42.08%. Over the last 30 days, the price of ABCL has fallen by 33.28%. And in the last five days, it has surged by 6.82%.
